TSX gains after CPI shows US inflation rose 3%
WALTHAM, Mass. - Revvity, Inc. (NYSE:RVTY), a $9.76 billion life sciences company with impressive fundamentals including a perfect Piotroski Score of 9, announced Monday the release of its Living Image Synergy AI multimodal analysis software designed for in vivo imaging researchers. The new platform unifies data analysis across optical, microCT, ultrasound, and other imaging modalities.
The software aims to reduce data inconsistencies, streamline workflows, increase throughput, and enhance reproducibility in preclinical imaging research. It centralizes analysis functions that previously required separate tools, allowing researchers to correlate datasets from different imaging technologies. According to InvestingPro analysis, Revvity maintains strong operational efficiency with a gross profit margin of 55.92% and a healthy current ratio of 3.33, indicating solid financial backing for its R&D initiatives.
"Our Living Image Synergy AI software marks a significant leap forward in preclinical imaging analysis," said Kevin Quick, VP of platforms at Revvity. "By unifying disparate analysis tools and integrating AI into existing workflows, Revvity’s new solution is directed towards enabling earlier insights and more consistent analysis across modalities."
The platform incorporates AI algorithms that automate image segmentation and region-of-interest quantification, tasks that have traditionally been labor-intensive and subject to variability. These features are designed to support high-throughput analysis and more efficient monitoring of disease progression and therapeutic efficacy.
Revvity will showcase the Living Image Synergy AI software at the WMIC conference in Anchorage, Alaska, taking place from Monday through October 3.
The company, which reported 2024 revenue of more than $2.7 billion and employs approximately 11,000 people, serves customers across pharmaceutical and biotech industries, diagnostic labs, academia, and governments in over 160 countries. Revvity is listed on the S&P 500 index.
This information is based on a press release statement from Revvity.
In other recent news, Revvity Inc has been the subject of multiple analyst revisions following its second-quarter earnings report. The company reported organic growth of 3%, aligning with consensus estimates, and earnings per share of $1.18, surpassing analyst expectations of $1.14 by 3.5%. Despite these results, several firms have adjusted their price targets for Revvity, citing challenges in the Chinese market as a significant factor. Stifel lowered its price target to $110 while maintaining a Hold rating, noting pressures in the China ImmunoDx sector. Raymond James also reduced its price target to $115, attributing the change to reimbursement headwinds in China affecting multiplex immunodiagnostics. Bernstein SocGen Group followed suit, setting their target at $115, while Jefferies decreased its target to $100 due to guidance adjustments related to China’s drug-related group policies. KeyBanc, however, reiterated its Overweight rating with a price target of $125, despite lowering estimates based on management’s comments about future operating margins and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.